New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
06:32 EDTWLP, CI, HS, WCG, AGP, MRK, JNJ, CNC, HNT, GSK, BMY, LLY, AZN, MOH, UNH, RHHBY, NVS, PFE, AET, HUM, SNYPatients paying much more for specialty drugs, NY Times says
The amount that patients with certain diseases must pay for specialty drugs has increased significantly, a research firm reported, according to The New York Times. Meanwhile, consumers' use of health care increased in 2013 for the firm time in three years, the newspaper quoted the firm, the IMS Institute for Healthcare Informatics, as saying. Publicly traded drug makers include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY). Publicly traded health insurers include AMERIGROUP (AGP), Aetna (AET), Centene (CNC), Cigna (CI), Health Net (HNT), Healthspring (HS), Humana (HUM), Molina Healthcare (MOH), UnitedHealth (UNH), WellCare (WCG) and WellPoint (WLP).Reference Link
News For AZN;JNJ;PFE;LLY;MRK;NVS;BMY;SNY;RHHBY;GSK;HUM;UNH;HNT;AET;MOH;CNC;AGP;HS;WLP;WCG;CI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>
April 7, 2015
07:41 EDTUNH, HNT, AET, WCG, CI, HUM2016 MA rates positive for first time in seven years, says Deutsche Bank
Deutsche Bank notes that for the first time since 2009, Medicare Advantage rates will be positive after the Centers for Medicare and Medicaid Services announced yesterday that final 2016 rates will rise by 1.25%, representing a 220 basis points favorable swing from the preliminary proposed cut of 0.95%. Deutsche says the positive surprise is "somewhat tempered" by the more cautious view on Medicare cost trends provided by the CMS actuaries in the final 2016 rate announcement. The firm expects Humana (HUM), Health Net (HNT) and UnitedHealth (UNH), Aetna (AET) and Anthem (ANTM) to experience Medicare Advantage rate increases.
07:39 EDTHNT, MOH, WCGSome managed care stocks could be pressured by CMS decision, says Stifel
Subscribe for More Information
07:14 EDTGSK, AZN, LLY, BMY, RHHBY, MRK, NVS, PFE, SNYEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
07:02 EDTPFEGlycoMimetics updates on Pfizer's plans to initiate Phase 3 Rivipansel trial
Subscribe for More Information
06:56 EDTAETAetna CEO sees 'groundswell' of wage increases in coming months, WSJ reports
Mark Bertolini, the CEO of Aetna, says he believes there will be a "groundswell" of pay increases for the lowest-paid employees at big companies in the next few months, The Wall Street Journal reports. Bertolini commented at a Peterson Institute for International Economics event that he believes "there are a number of CEOs that will come out in the next six months with wage increases that will matter." Reference Link
05:48 EDTUNHCatamaran downgraded to Hold from Buy at Jefferies
Subscribe for More Information
April 6, 2015
16:17 EDTBMYOn The Fly: Closing Wrap
Subscribe for More Information
14:34 EDTJNJDepomed price target raised to $30 from $27 at Roth Capital
Subscribe for More Information
13:12 EDTUNHCatamaran purchase expected to clear antitrust hurdles, CT Financial News says
Optum, a unit of UnitedHealth (UNH), is expected to face close scrutiny by regulators over its proposed acquisition of Catamaran (CTRX) and its pharmacy benefits management unit, but the deal is likely to be approved by regulators, CT Financial News reports, adding that the prospective deal could start a wave of consolidation among PBMs. Norm Smith, president and founder of health care research firm Viewpoint Consulting, believes the ultimate beneficiaries of the OptumRx/Catamaran deal will be consumers and health insurers. Reference Link
12:44 EDTBMYOn The Fly: Midday Wrap
Subscribe for More Information
12:13 EDTBMYuniQure price target raised to $40 from $35 at Piper Jaffray
Subscribe for More Information
10:37 EDTPFETargacept says Pfizer terminates research & license agreement with Catalyst
In a regulatory filing from earlier, Targacept (TRGT) said: "As previously reported, on March 5, Targacept, Talos Merger Sub, a Delaware corporation and a wholly owned subsidiary of Targacept and Catalyst Biosciences, entered into an Agreement and Plan of Merger, pursuant to which, among other things, subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, Merger Sub will merge with and into Catalyst, with Catalyst becoming a wholly owned subsidiary of Targacept and the surviving corporation of the merger. On April 1, Catalyst notified Targacept that Pfizer (PFE) would be exercising its right to terminate in its entirety the June 29, 2009, research and license agreement between Catalyst and Wyeth, which governs the development and commercialization of Catalystís leading human Factor VIIa product candidate for the treatment of hemophilia and surgical bleeding indications. On April 2, Pfizer provided Catalyst with its formal written notice of termination of the research and license agreement. Upon the June 1, effective date of the termination, the license and certain rights under the research and license agreement will terminate and revert to Catalyst. Catalyst has informed Targacept that Pfizer is committed to an orderly transfer of data, regulatory documentation and related technology under the agreement to Catalyst to enable Catalyst to continue the clinical development of this product candidate. Targacept is currently reviewing the implications of this event on the proposed Merger. In morning trading shares of Targacept are down almost 12% to $2.51.
09:36 EDTJNJActive equity options trading on open
Subscribe for More Information
08:13 EDTNVSJuno Therapeutics announces patent litigation settlement
Subscribe for More Information
08:13 EDTBMYCelldex announces initiation of Phase 1/2 study of Varlilumab combination
Subscribe for More Information
07:57 EDTMOH, UNH, HNT, CNC, WCG, HUM, CI, AETLeerink healthcare services analyst holds analyst/industry conference call
Healthcare Services Analyst Gupte discusses the leverage Anthem likely has in its Pharmacy Benefit Manager (PBM) contract with Express Scripts and how it changes after the Catamaran-Optum Rx deal, the synergy potential for the deal between Catamaran and Optum Rx and the likelihood of Cigna-HS remaining with the newly merged Optum Rx-CTRX on an Analyst/Industry conference call to be held on April 6 at 2 pm.
07:33 EDTBMYBristol-Myers announces strategic collaboration with uniQure
Subscribe for More Information
07:14 EDTLLYBiodel GEM device demonstrates 'superior' usability
Biodel (BIOD) announced results from a formative human factors study of its Glucagon Emergency Management, or GEM, device, which is in development for the treatment of diabetes patients experiencing severe hypoglycemia. In the study, the GEM device demonstrated a substantial improvement in ease-of-use and successful delivery of the full dose, as well as a reduction in dosing errors, when compared to commercially available glucagon kits; Eli Lilly's (LLY) Glucagon Emergency Rescue Kit and Novo Nordisk's GlucaGen HypoKit. Furthermore, while training and previous experience increased the success rate with the Eli Lilly and Novo Nordisk glucagon kits, it did not further impact the already high success rate with the GEM device when compared to non-experienced, untrained participants.
06:21 EDTJNJJohnson & Johnson CEO comments on Asia expansion, WSJ reports
Subscribe for More Information
April 5, 2015
09:06 EDTUNHUnitedHealth looks expensive, Barron's says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | 6 | 7 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use